Physiomics

PYCHealthcare
0.4750GBX
0.00%
Market Cap
1.44M
Volume
1.25M
14% of avg
P/E Ratio
-0.01
EPS (TTM)
-0.34
Beta
0.56
Day Range
0.4500p - 0.4710p
52 Week Range
0.3800p0.4750p1.4000p
0.4750p

Upcoming Events

August 2025
Completion of new contract with UK biotech firm
High Impact Event
9 August 2025
Completion of the current contract project
September 2025
Anticipated release of full-year results
High Impact Event
27 September 2025
Expected Annual Results Release for FY 2025
High Impact Event
Q4 2025
Expected completion of Innovate UK funded PREDICT-ONC trial
High Impact Event
Early 2026
Completion of Innovate funded clinical trial to further refine and validate the personalised dosing software
High Impact Event
30 June 2026
Majority of contract value to be recognised
High Impact Event
31 December 2026
First in Human clinical trial
High Impact Event
PYC
NEUTRAL

Physiomics Implements Personalised Dosing Software on DoseMeRx Platform

The healthcare company has successfully implemented its personalised dosing software onto the DoseMeRx platform and expanded its partnership with DoseMe.

PYC
GOOD

Physiomics Secures New Contract for Non-Oncology Therapeutic Development

The healthcare technology company has secured a new contract to apply its modelling and simulation expertise to support the development of a non-oncology therapeutic for an existing client.

PYC
GOOD

Physiomics Secures Two New Biometrics Contracts

The healthcare consulting firm has secured two new contracts worth £111,000 to provide Biostatistical Consulting and Statistical Programming services to a UK-based biopharmaceutical company. The company has also appointed a new Head of Biometrics to lead this new service line.

PYC
GOOD

Physiomics Awarded Sizeable Contract Extension

The biotechnology company has been awarded a sizeable contract extension by an existing large pharma client, building on a previous deal. The project is valued at £143,780 and is expected to complete over the next six months.

PYC
GOOD

Physiomics Secures New UK Contract for Rheumatoid Arthritis Treatment

The healthcare company has secured a new contract with a UK client to provide modelling and simulation services for a rheumatoid arthritis treatment program.

PYC
NEUTRAL

Physiomics Provides Update on Director's Involvement with Company in Administration

The healthcare company provides an update on a non-executive director's role at another firm that has entered administration.

PYC
GOOD

Physiomics Awarded New Contract

The healthcare company has secured a new contract worth £47,600 to provide modelling and simulation services for the development of a novel antibody therapy.

PYC
NEUTRAL

Physiomics Publishes Peer-Reviewed Article on Immunotherapy Drug Development

The biotechnology company has published a peer-reviewed article on its mathematical modelling approach to supporting the development of a novel immunotherapy drug.

PYC
GOOD

Physiomics Awarded New Contract by Numab Therapeutics

The healthcare company has been awarded a new contract by Numab Therapeutics to apply modelling and simulation techniques to support pre-clinical development of a cancer treatment.

PYC
GOOD

Physiomics Wins New Contract with UK Biotech Firm

The healthcare technology company has secured a new contract with a UK biotech firm to develop a pharmacokinetic and pharmacodynamic model for an upcoming clinical trial.

Protecting and respecting your privacy

We use cookies and similar technologies to help us improve your experience. This includes essential cookies for site functionality and Google Analytics to understand how visitors interact with our website. You can read more about how we use cookies in our Cookie Policy.